Skip to main
LPCN

Lipocine (LPCN) Stock Forecast & Price Target

Lipocine (LPCN) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lipocine is a clinical-stage biopharmaceutical company that is focused on the development and commercialization of oral delivery solutions for existing drugs, with its lead product candidate TLANDO showing promising results in its Phase 3 PPD trial. The company's strong financials, including a net loss of $3.2M and total revenue of $0.1M in the 3Q25, suggest its ability to continue its research and development efforts. With its continued progress and potential in the emerging treatment market for postpartum depression, Lipocine's stock has a positive outlook for growth in the future.

Bears say

Lipocine is a clinical-stage biopharmaceutical company that is heavily reliant on its proprietary drug delivery technology to drive its future growth. However, the company has a limited pipeline and a significant portion of its revenue comes from developing products for corporate partners, making it vulnerable to collaboration setbacks. Additionally, Lipocine has a history of incurring losses and its current cash reserves are significantly lower than its long-term debt, suggesting potential financial difficulties in the future.

Lipocine (LPCN) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lipocine and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lipocine (LPCN) Forecast

Analysts have given Lipocine (LPCN) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Lipocine (LPCN) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lipocine (LPCN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.